Table 1: Patients distribution.

CategoryAMLALLCMLMDSMMLDSAATotal

Sex
Male33 (55.9%)30 (62.5%)45 (59.2%)6 (37.5%)1 (100%)12 (44.4%)29 (56.9%)156 (56.1%)
Female26 (44.1%)18 (37.5%)31 (40.8%)10 (62.5%)015 (55.6%)22 (43.1%)122 (43.9%)

Source
BM49 (83.1%)41 (85.4%)63 (82.9%)11 (68.8%)07 (25.9%)49 (96.1%)220 (79.1%)
PBSC10 (16.9%)3 (6.3%)13 (17.1%)4 (25%)1 (100%)20 (74.1%)1 (2%)52 (18.7%)
CB 04 (8.3%)01 (6.3%)001 (2%)6 (2.2%)

Regimen
Myeloablative58 (98.3%)48 (100%)76 (100%)12 (75%)0046 (90.2%)241 (86.7%)
RIC1 (1.7%)004 (25%)1 (100%)27 (100%)5 (9.8%)37 (13.3%)

Patient age
Median351536.53531432032
Range1–551–477–572–553118–565–511–57

Age
<2014 (23.7%)27 (56.3%)6 (7.9%)4 (25%)02 (7.4%)26 (51%)79 (28.4%)
20–4027 (45.8%)16 (33.3%)40 (52.6%)6 (37.5%)1 (100%)10 (37%)19 (37.3%)119 (42.8%)
>4018 (30.5%)5 (10.4%)30 (39.5%)6 (37.5%)015 (55.6%)6 (11.8%)80 (28.8%)

Disease stage
Early28 (47.5%)18 (37.5%)60 (78.9%)16 (100%)02 (7.4%)51 (100%)175 (62.9%)
Intermediate17 (28.8%)23 (47.9%)12 (15.8%)01 (100%)7 (25.9%)60 (21.6%)
Advanced14 (23.7%)7 (14.6%)4 (5.3%)0018 (66.7%)43 (15.5%)

Time interval
<12 months24 (40.7%)13 (27.1%)13 (17.1%)5 (31.3%)01 (3.7%)36 (70.6%)92 (33.1%)
>12 months35 (59.3%)35 (72.9%)63 (82.9%)11 (68.7%)1 (100%)26 (96.3%)15 (29.45)186 (66.9%)

HLA
HLA IS50 (84.7%)33 (68.8%)69 (90.8%)14 (87.5%)1 (100%)27 (100%)44 (86.3%)238 (85.6%)
Unrelated9 (15.35)15 (31.3%)7 (9.2%)2 (12.5%)007 (13.7%)40 (14.4%)

Gender com
Other42 (71.2%)34 (70.8%)58 (76.3%)16 (100%)021 (77.8%)38 (74.5%)209 (75.2%)
DF/RM17 (28.8%)14 (29.2%)18 (23.7%)01 (100%)6 (22.2%)13 (25.5%)69 (24.8%)

Score
02 (3.4%)4 (8.3%)1 (1.3%)2 (12.5%)0013 (25.5%)22 (7.9%)
110 (16.9%)6 (12.5%)7 (9.2%)4 (25%)0018 (35.3%)45 (16.2%)
217 (28.8%)12 (25%)20 (26.3%)3 (18.8%)01 (3.7%)13 (25.5%)66 (23.7%)
39 (15.3%)12 (25%)35 (46.1%)7 (15.3%)03 (11.1%)6 (11.8%)72 (25.9%)
410 (16.9%)11 (22.9%)9 (11.8%)01 (100%)11 (40.7%)1 (2.0%)43 (15.5%)
58 (13.6%)2 (4.2%)4 (5.3%)0011 (40.7%)025 (9.0%)
63 (5.1%)1 (2.1%)0001 (3.7%)05 (1.8%)

CMV
Recipient pos52 (91.2%)37 (77.1%)65 (85.5%)14 (87.5%)1 (100%)23 (88.5%)46 (90.2%)238 (86.5%)
Recipient neg5 (8.8%)11 (22.9%)11 (14.5%)2 (12.5%)03 (11.5%)5 (9.8%)37 (13.5%)

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; LD: lymphoproliferative disorders; SAA: severe aplastic anemia; BM: bone marrow; PBSC: peripheral blood stem cell; CB: cord blood; HLA IS: human leukocyte antigen identical sibling; Gender com: gender combination between donor and recipient; DF/RM: donor female/recipient male; CMV: cytomegalovirus; neg: negative; pos: positive.